MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial - Poll - MDSpire

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

  • By

  • Martin Wermke

  • Sebastian Ochsenreither

  • Dirk Jaeger

  • Heiko Becker

  • Annalen Bleckmann

  • Farastuk Bozorgmehr

  • Manik Chatterjee

  • Stefanie Groepper

  • Mathias Haenel

  • Judith S. Hecker

  • Max-Felix Häring

  • Daniel Heudobler

  • Norbert Hilf

  • Martin Hofmann

  • Meike Hutt

  • Andrea Mayer-Mokler

  • Sarah Missel

  • Manuel Ruh

  • Heiko Schuster

  • Olga Veremchuk

  • Moritz Kleemiss

  • Stefan Knop

  • Simon Laban

  • Martin Sebastian

  • Silvia Spoerl

  • Cedrik Michael Britten

  • Carsten Reinhardt

  • May 31, 2026

Share

Original Source(s)

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

  • by Martin Wermke, Sebastian Ochsenreither, Dirk Jaeger, Heiko Becker, Annalen Bleckmann, Farastuk Bozorgmehr, Manik Chatterjee, Stefanie Groepper, Mathias Haenel, Judith S. Hecker, Max-Felix Häring, Daniel Heudobler, Norbert Hilf, Martin Hofmann, Meike Hutt, Andrea Mayer-Mokler, Sarah Missel, Manuel Ruh, Heiko Schuster, Olga Veremchuk, Moritz Kleemiss, Stefan Knop, Simon Laban, Martin Sebastian, Silvia Spoerl, Cedrik Michael Britten, Carsten Reinhardt

  • May 31, 2026

Related Content

Real-world healthcare resource use and costs associated with the management of locally advanced head and neck cancer in Portugal – TRACE2 study

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy